SIC
ONC

SJS Investment Consulting’s BeOne Medicines Ltd ONC Stock Holding History

SJS Investment Consulting’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$5K Hold
27
– – ﹤0.01% 451
2021
Q4 		$7K Buy
+27
New +$9.12K ﹤0.01% 405

Other funds holding ONC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CII
Capital International Inc Los Angeles, California $13B AUM 31.88% 1-Year Est. Return

SJS Investment Consulting's ONC Position: Q1 2022 in Review

SJS Investment Consulting held its BeOne Medicines Ltd (ONC) position steady in Q1 2022 at 27 shares worth $5K. The position accounts for ﹤0.01% of the portfolio, ranked #451.

SJS Investment Consulting first reported a position in ONC in Q4 2021 and has held it in 2 quarters since. The position peaked at $7K in Q4 2021. 238 funds tracked by Wall St. Rank hold ONC as of Q1 2022.

  • SJS Investment Consulting held 27 shares of BeOne Medicines Ltd worth $5K as of Q1 2022.
  • SJS Investment Consulting left its BeOne Medicines Ltd share count unchanged in Q1 2022.
  • BeOne Medicines Ltd made up ﹤0.01% of SJS Investment Consulting's portfolio in Q1 2022, its #451 holding.
  • SJS Investment Consulting first reported a position in BeOne Medicines Ltd in Q4 2021 and has held it in 2 quarters since.
  • SJS Investment Consulting's BeOne Medicines Ltd position peaked at $7K in Q4 2021.
  • 238 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q1 2022.

Based on SJS Investment Consulting's 13F filing for Q1 2022, filed 5 May 2022.